Hartnick, Christopher JSkotko, Brian Gary
Summary
Down syndrome (DS) is one of the most common genetic conditions in the United States with a prevalence rate estimated at 6.7 people with DS per 10,000 of the population in 2010 and is characterized by global developmental delays, intellectual disability, and obstructive sleep apnea (OSA), which can have negative effects on daily life for children with DS. Hypoglossal nerve stimulation (HGS) is a novel therapy for OSA in adults as well as children with preliminary data suggesting improved cognition and language in this population. Therefore, this proposal is a formal clinical trial to focus upon the effects on neurocognition and expressive language before and after hypoglossal nerve stimulation treatment of OSA.
Down Syndrome Publications
Brain sciences2021